omh1 Antibody

What is OPHN1 protein and why is it an important research target?

OPHN1 (Oligophrenin-1) is a protein that stimulates GTP hydrolysis of members of the Rho family. Its action on RHOA activity and signaling is implicated in the growth and stabilization of dendritic spines, making it critical for synaptic function. OPHN1 is essential for stabilizing AMPA receptors at postsynaptic sites and regulating synaptic vesicle endocytosis at presynaptic terminals. Additionally, it's required for the localization of NR1D1 to dendrites, can suppress its repressor activity, and protect it from proteasomal degradation . OPHN1 functions as a bridge in cellular pathways by interacting with other proteins such as PAK3 and WAVE proteins to regulate actin organization, highlighting its pivotal role in dendritic spine formation and maintenance that affects structural synaptic changes .

What types of OPHN1 antibodies are available for research applications?

Based on available information, OPHN1 antibodies are commercially available as rabbit polyclonal antibodies. For example, ab229655 is a rabbit polyclonal antibody that reacts with human samples and has been verified for Western blot (WB) and immunohistochemistry-paraffin (IHC-P) applications . The immunogen used corresponds to a recombinant fragment protein within Human Oligophrenin-1 amino acids 1-300 . Research facilities like the Human Antibody Core Facility at OMRF have capabilities to produce fully-human, full-length, antigen-specific antibodies for various targets, suggesting that custom OPHN1 antibodies could potentially be developed through such specialized facilities .

What are the validated applications for OPHN1 antibodies?

OPHN1 antibodies have been validated for the following research applications:

The antibody has been observed to detect a band at the predicted molecular weight of 92 kDa in A549 (human lung carcinoma cell line) whole cell lysate . While these applications have been confirmed, researchers should perform their own validation when applying the antibody to new experimental contexts or sample types.

How should I design proper controls for OPHN1 antibody experiments?

When designing experiments using OPHN1 antibodies, implementing appropriate controls is essential for ensuring reliable and interpretable results:

• Positive controls: Include samples known to express OPHN1, such as A549 human lung carcinoma cell line for Western blot , or human colon and gastric cancer tissues for IHC-P .

• Negative controls:

  • Primary antibody omission: Process samples without adding the primary OPHN1 antibody

  • Isotype control: Use a non-specific antibody of the same isotype (rabbit polyclonal IgG)

  • Blocking peptide: Pre-incubate the antibody with its specific immunogen to demonstrate specificity

• Loading controls: For Western blots, include detection of housekeeping proteins (e.g., GAPDH, actin, tubulin) to ensure equal loading and transfer.

• Tissue/cell type controls: Include samples with known variable expression levels of OPHN1 to validate differential detection capability.

Remember that validating antibody specificity is crucial for reliable results, especially when investigating protein-protein interactions involving OPHN1's role in Rho family GTPase pathways and dendritic spine formation.

What are the optimal sample preparation methods for detecting OPHN1 using antibodies?

For optimal detection of OPHN1 in different experimental contexts, sample preparation should be tailored to the specific application:

Western Blot (WB) Sample Preparation:

• Prepare whole cell lysates using a buffer containing appropriate protease inhibitors to prevent OPHN1 degradation

• For A549 cells, successful detection has been demonstrated with standard cell lysis protocols

• Use a reducing agent in sample buffer as OPHN1 contains disulfide bonds

• Denature samples at 95°C for 5 minutes before loading

• Load sufficient protein (typically 20-50 μg total protein) to ensure detection of OPHN1 at its predicted 92 kDa size

Immunohistochemistry-Paraffin (IHC-P) Sample Preparation:

• Fix tissues in 10% neutral buffered formalin for 24-48 hours

• Process tissues through graded alcohols and xylene before embedding in paraffin

• Section tissues at 4-6 μm thickness

• Perform heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Block endogenous peroxidase activity with hydrogen peroxide

• Apply protein blocking solution to reduce non-specific binding

• Incubate with primary OPHN1 antibody at a 1/100 dilution

These methods have been validated for human samples including cancer tissues and cell lines, though optimization might be required for different experimental contexts.

How should I approach OPHN1 antibody validation in my specific experimental system?

Validating OPHN1 antibodies in your specific experimental system requires a multi-faceted approach:

• Expression verification:

  • Confirm OPHN1 expression in your model system using orthogonal methods (RT-PCR, RNA-seq)

  • Compare antibody detection with known expression patterns in different tissues/cell types

• Knockout/knockdown validation:

  • Generate OPHN1 knockout or knockdown systems (CRISPR-Cas9, siRNA, shRNA)

  • Demonstrate reduction or absence of signal with the antibody in these systems

• Multiple antibody comparison:

  • Use antibodies from different suppliers or those recognizing different epitopes

  • Compare detection patterns to confirm consistency

• Analysis of binding specificity:

  • Perform immunoprecipitation followed by mass spectrometry to identify pulled-down proteins

  • Verify that OPHN1 is the predominant protein detected

• Cross-reactivity assessment:

  • Test antibody against cell lines/tissues from different species if cross-reactivity is claimed

  • Verify epitope conservation through sequence alignment

• Functional validation:

  • Correlate antibody staining with known OPHN1 functions in dendritic spine formation

  • Verify detection in subcellular locations consistent with OPHN1's role in synaptic function

Following these validation steps will ensure reliable and reproducible results when using OPHN1 antibodies in your specific experimental system.

How can I address non-specific binding issues with OPHN1 antibodies?

Non-specific binding is a common challenge when working with antibodies. For OPHN1 antibodies, consider these methodological solutions:

• Optimize blocking conditions:

  • Increase blocking agent concentration (5% BSA or milk)

  • Extend blocking time to 2 hours at room temperature

  • Test alternative blocking agents (normal serum matching secondary antibody species)

• Adjust antibody concentrations:

  • Perform titration experiments to determine optimal concentration

  • For Western blots, dilutions beyond the recommended 1/1000 might reduce background

  • For IHC-P, try more dilute solutions than the recommended 1/100

• Modify washing steps:

  • Increase wash buffer stringency (add 0.1-0.3% Triton X-100 or 0.1% SDS)

  • Extend washing times and increase number of washes

  • Use gentle agitation during washing steps

• Modify incubation conditions:

  • Incubate antibody at 4°C overnight instead of room temperature

  • Add 0.1% Triton X-100 to antibody diluent to reduce hydrophobic interactions

• Pre-adsorb the antibody:

  • Incubate with tissues/cells lacking OPHN1 to remove cross-reactive antibodies

  • Use acetone powder from non-expressing tissues to pre-clear antibody solution

For persistent non-specific binding issues, consider alternative detection methods or consulting with the antibody manufacturer for specific recommendations regarding their OPHN1 antibody product.

What are the common pitfalls in interpreting OPHN1 antibody experimental results?

When interpreting results from OPHN1 antibody experiments, researchers should be aware of these common pitfalls:

• Misinterpreting non-specific bands:

  • OPHN1 has a predicted molecular weight of 92 kDa , but post-translational modifications may alter migration patterns

  • Degradation products can appear as lower molecular weight bands

  • Always include positive controls with known OPHN1 expression

• Overlooking context-dependent expression:

  • OPHN1 expression may vary significantly between cell types and tissues

  • Developmental stages may affect expression levels

  • Consider cellular stress conditions that might alter expression or localization

• Signal-to-noise ratio issues:

  • Weak specific signals might be obscured by background staining

  • Optimize detection methods for low abundance proteins

  • Consider signal amplification techniques for tissues with low expression

• Overlooking subcellular localization:

  • OPHN1 functions in dendritic spines and synapses, requiring high-resolution imaging

  • Co-localization with synaptic markers may help confirm specific staining

  • Diffuse cytoplasmic staining might indicate non-specific binding or altered localization

• Inadequate quantification:

  • Apply appropriate quantification methods for signal intensity

  • Use standardized exposure times for image acquisition

  • Include loading controls and normalization procedures

• Failing to account for splice variants:

  • Verify which OPHN1 isoforms are recognized by your antibody

  • Different antibodies may detect different epitopes and therefore different isoforms

Careful experimental design, inclusion of appropriate controls, and critical analysis of results will minimize misinterpretation of OPHN1 antibody experimental data.

How should I determine the optimal antibody concentration for my specific application?

Determining the optimal concentration of OPHN1 antibody requires systematic titration for each specific application and experimental system:

Western Blot Titration Method:

• Prepare a dilution series of the OPHN1 antibody (e.g., 1:500, 1:1000, 1:2000, 1:5000)

• Use identical sample amounts on each blot strip

• Process all samples simultaneously with the same secondary antibody concentration

• Evaluate results based on:

  • Signal-to-noise ratio

  • Specific band intensity at 92 kDa

  • Background levels

• For OPHN1 antibody ab229655, start with the recommended 1:1000 dilution

IHC-P Titration Method:

• Prepare serial sections of the same tissue block

• Apply antibody at different concentrations (e.g., 1:50, 1:100, 1:200, 1:500)

• Process all sections simultaneously with identical protocols

• Evaluate results based on:

  • Specific staining pattern

  • Signal intensity

  • Background staining

• For OPHN1 antibody ab229655, begin with the recommended 1:100 dilution

Optimization Table Example:

Document all optimization results systematically to establish reproducible protocols for your specific experimental system.

How can I apply OPHN1 antibodies in protein-protein interaction studies?

OPHN1 antibodies can be powerful tools for investigating protein-protein interactions, particularly given OPHN1's role as a bridge in cellular pathways where it interacts with proteins like PAK3 and WAVE proteins to regulate actin organization . Here's a methodological approach:

• Co-immunoprecipitation (Co-IP):

  • Use OPHN1 antibody coupled to protein A/G beads to pull down OPHN1 and its interacting partners

  • Include appropriate controls (IgG, lysate input)

  • Identify pulled-down proteins by Western blot or mass spectrometry

  • Verify interactions with reciprocal Co-IPs using antibodies against suspected binding partners

• Proximity Ligation Assay (PLA):

  • Use OPHN1 antibody in combination with antibodies against suspected interaction partners

  • This technique allows visualization of protein interactions in situ with high sensitivity

  • Quantify interaction signals in different subcellular compartments or experimental conditions

• FRET/BRET Analysis:

  • Express OPHN1 and potential binding partners with appropriate fluorescent/luminescent tags

  • Use OPHN1 antibody to confirm expression and localization in parallel experiments

  • Measure energy transfer to detect close proximity between proteins

• Pull-down Assays with Protein Domains:

  • Express specific domains of OPHN1 as recombinant proteins

  • Use OPHN1 antibody to validate domain expression

  • Perform pull-down assays to identify domain-specific interactions

• Cross-linking Mass Spectrometry:

  • Cross-link proteins in intact cells or tissues

  • Immunoprecipitate with OPHN1 antibody

  • Identify cross-linked peptides by mass spectrometry to map interaction interfaces

These approaches, when used in combination, can provide robust evidence for OPHN1's interactions with partners involved in dendritic spine formation and synaptic function.

What strategies can I use to investigate OPHN1's role in dendritic spine dynamics?

Given OPHN1's critical role in dendritic spine formation and synaptic function, these methodological approaches can be employed using OPHN1 antibodies:

• Time-course immunofluorescence microscopy:

  • Use OPHN1 antibody for immunofluorescence at different developmental stages

  • Co-stain with dendritic spine markers (e.g., PSD-95, F-actin)

  • Quantify changes in OPHN1 localization during spine maturation

  • Correlate OPHN1 expression with spine morphology using 3D reconstruction

• Super-resolution microscopy:

  • Apply techniques like STED, PALM, or STORM with OPHN1 antibody

  • Resolve OPHN1 localization within spine subcompartments

  • Co-localize with Rho family GTPases to confirm functional interactions

  • Track dynamic changes in response to synaptic activity

• Live-cell imaging with antibody fragments:

  • Generate Fab fragments from OPHN1 antibodies for live-cell applications

  • Conjugate to cell-permeable peptides and fluorophores

  • Monitor real-time dynamics of endogenous OPHN1 during spine remodeling

• Correlative light and electron microscopy (CLEM):

  • Use OPHN1 antibody for immunogold labeling

  • Combine with ultrastructural analysis of spine morphology

  • Determine precise localization of OPHN1 at the ultrastructural level

• Activity-dependent redistribution:

  • Stimulate neurons with paradigms that induce LTP or LTD

  • Use OPHN1 antibody to track redistribution

  • Quantify changes in synaptic vs. extrasynaptic OPHN1 localization

• Dendritic spine morphometric analysis:

  • Manipulate OPHN1 expression or function

  • Use antibody to confirm changes in protein levels

  • Measure effects on spine density, size, and morphology

These methodologies can provide comprehensive insights into how OPHN1 contributes to the dynamic regulation of dendritic spines and synaptic function.

How can I leverage OPHN1 antibodies for studying neurodevelopmental disorders?

OPHN1 has important implications for neurodevelopmental research, as it plays a role in synaptic function, dendritic spine formation, and stabilization of AMPA receptors . Here are methodological approaches using OPHN1 antibodies:

• Patient-derived cell analysis:

  • Use OPHN1 antibodies to compare expression and localization in patient-derived neurons or iPSCs

  • Quantify differences in protein levels, post-translational modifications, or subcellular distribution

  • Correlate with phenotypic characteristics or genetic variants

• Brain tissue immunohistochemistry:

  • Apply OPHN1 antibody to post-mortem brain tissue from individuals with neurodevelopmental disorders

  • Compare with control samples for expression patterns

  • Analyze region-specific alterations in expression or localization

  • Use multiplexed immunofluorescence to examine co-localization with synaptic markers

• Animal model validation:

  • Use OPHN1 antibodies to validate knockout/knockin animal models

  • Perform immunohistochemistry across developmental timepoints

  • Correlate protein expression with behavioral phenotypes

  • Examine effects of therapeutic interventions on OPHN1 expression or localization

• Circuit-specific analysis:

  • Combine OPHN1 immunostaining with circuit tracers

  • Identify circuit-specific alterations in protein expression

  • Relate to functional connectivity measures

• Proteomic profiling:

  • Use OPHN1 antibodies for immunoprecipitation followed by mass spectrometry

  • Compare protein interaction networks between control and disorder conditions

  • Identify altered molecular pathways

• Drug screening applications:

  • Develop high-content screening assays using OPHN1 antibodies

  • Identify compounds that normalize OPHN1 expression or localization

  • Validate hits with functional assays of synaptic transmission

These approaches can provide valuable insights into the role of OPHN1 in neurodevelopmental disorders and potentially identify new therapeutic targets or biomarkers.

What emerging technologies might enhance OPHN1 antibody-based research?

Several cutting-edge technologies show promise for advancing OPHN1 antibody applications:

• Engineered antibody fragments and nanobodies:

  • Smaller antibody formats may provide better tissue penetration and spatial resolution

  • Single-domain antibodies could access epitopes unavailable to conventional antibodies

  • Reduced size enables superior resolution in super-resolution microscopy applications

• Spatially-resolved proteomics:

  • Combining OPHN1 antibody staining with methods like Imaging Mass Cytometry

  • Detecting multiple proteins simultaneously in tissue sections

  • Creating detailed protein interaction maps with subcellular resolution

• Antibody-based biosensors:

  • Developing FRET-based sensors using OPHN1 antibody fragments

  • Real-time monitoring of OPHN1 conformational changes

  • Detecting OPHN1 activation states in living cells

• CRISPR-based tagging combined with antibody detection:

  • Precisely tagging endogenous OPHN1 with minimal epitope tags

  • Using highly specific antibodies against the tag

  • Preserving native regulation while enabling specific detection

• Single-cell antibody-based proteomics:

  • Applying methods like CITE-seq with OPHN1 antibodies

  • Correlating protein expression with transcriptomics at single-cell resolution

  • Identifying cell type-specific OPHN1 expression patterns

These emerging technologies could significantly enhance our ability to study OPHN1's role in neuronal function and provide new insights into related neurological disorders.

How might computational approaches improve OPHN1 antibody specificity and experimental design?

Computational approaches are increasingly valuable for enhancing antibody research, including studies involving OPHN1:

• Epitope prediction and antibody design:

  • Computational models can predict optimal epitopes for OPHN1 recognition

  • Machine learning algorithms can help design antibodies with improved specificity

  • In silico modeling of antibody-antigen interactions can guide experimental design

• Cross-reactivity prediction:

  • Algorithms can screen for potential cross-reactive proteins with similar epitopes

  • This enables more informed control selection and experiment interpretation

  • Protein databases can be searched for sequences with homology to OPHN1 epitopes

• Image analysis automation:

  • Machine learning algorithms can quantify OPHN1 staining patterns in complex tissues

  • Deep learning approaches can segment subcellular compartments for detailed localization analysis

  • Automated detection of co-localization with interacting partners

• Experiment optimization through modeling:

  • Computational modeling of antibody binding kinetics can guide concentration optimization

  • Virtual experiments can predict optimal conditions for various applications

  • Statistical power analysis can determine appropriate sample sizes

• Network analysis for interaction studies:

  • Computational prediction of OPHN1 protein-protein interactions

  • Integration of experimental antibody data with predicted interaction networks

  • Prioritization of candidate interactions for experimental validation

As demonstrated in recent research on antibody specificity inference , computational models can successfully disentangle different binding modes, even when associated with chemically similar ligands, and enable the computational design of antibodies with customized specificity profiles. These approaches could be applied to develop OPHN1 antibodies with enhanced specificity and tailored binding properties.